Can you provide a detailed case report of a 28‑year‑old African‑American woman with systemic lupus erythematosus presenting with three months of fatigue, symmetric polyarthritis of the hands and knees, photosensitive malar rash, intermittent low‑grade fever, positive antinuclear antibody (ANA) at 1:1280 speckled pattern, markedly elevated anti‑double‑stranded DNA antibodies, low complement C3 and C4, and proteinuria consistent with early lupus nephritis (Class III), including her treatment regimen and six‑month follow‑up outcomes?

Case Report: Systemic Lupus Erythematosus with Class III Lupus Nephritis

Patient Presentation

A 28-year-old African-American woman presented with a 3-month history of fatigue, symmetric polyarthritis affecting hands and knees, photosensitive malar rash, and intermittent low-grade fever.

Laboratory Findings

• ANA: 1:1280 (speckled pattern)
• Anti-dsDNA antibodies: Markedly elevated
• Complement levels: Low C3 and C4
• Urinalysis: Proteinuria
• Renal biopsy: Class III lupus nephritis (focal proliferative)

Initial Treatment Regimen

This patient requires combined immunosuppressive therapy with glucocorticoids plus mycophenolate mofetil (MMF) as first-line treatment for Class III lupus nephritis 1.

Induction Therapy (Months 0-6)

Immunosuppression:

• Mycophenolate mofetil: 2-3 g/day (or mycophenolic acid equivalent) for 6 months
• Glucocorticoids: Moderate-dose regimen preferred over high-dose
  • Initial pulse methylprednisolone 250-500 mg IV for 1-3 days, followed by
  • Oral prednisone 0.5 mg/kg/day (maximum 30-40 mg/day), with rapid taper over 6-12 weeks to ≤7.5 mg/day

Adjunctive Therapy (Universal for All SLE Patients):

• Hydroxychloroquine: 5 mg/kg/day (approximately 400 mg/day for this patient) - mandatory for all SLE patients 1, 2
• RAS blockade: ACE inhibitor or ARB for proteinuria management and blood pressure control (target <130/80 mmHg) 1
• Aspirin: Low-dose (81 mg daily) for cardiovascular protection, especially given African-American ethnicity and increased CV risk 1

Important Considerations:

• Cyclophosphamide is an alternative if MMF unavailable or contraindicated, but MMF is preferred due to better tolerability and similar efficacy 1
• Voclosporin plus MMF showed superior outcomes in recent trials but may not be universally available 1
• Belimumab can be added to standard therapy for enhanced response rates 3

Supportive Measures

Infection Prophylaxis:

• Screen for hepatitis B, hepatitis C, HIV, and tuberculosis before starting immunosuppression 1
• Consider Pneumocystis jirovecii prophylaxis (trimethoprim-sulfamethoxazole) if lymphopenia present or high-dose steroids used
• Assess herpes zoster history; consider recombinant zoster vaccine

Bone Protection:

• Calcium 1200-1500 mg/day and vitamin D supplementation
• Baseline bone density assessment
• Bisphosphonates if high fracture risk 1

Fertility Preservation:

• Critical discussion required: Offer gonadotropin-releasing hormone agonist (leuprolide) during cyclophosphamide if used
• Discuss oocyte cryopreservation options before starting therapy 1
• Contraception counseling (avoid estrogen-containing methods if antiphospholipid antibodies present)

Sun Protection:

• Broad-spectrum sunscreen daily
• Minimize UV exposure given photosensitive rash 1

Six-Month Follow-Up Assessment

Response Criteria 1

Complete Response (Target Outcome):

• Proteinuria <0.5 g/g (protein-creatinine ratio <50 mg/mmol)
• Stable or improved kidney function (eGFR within ±10-15% of baseline)
• No rescue therapy required
• Expected timeframe: 6-12 months (may take >12 months in some patients)

Partial Response (Acceptable Outcome):

• ≥50% reduction in proteinuria AND proteinuria <3 g/g (300 mg/mmol)
• Stable or improved kidney function (±10-15% of baseline)

No Response:

• Failure to achieve partial or complete response by 6-12 months
• Action required: Switch to alternative immunosuppression (cyclophosphamide if not used initially, or add belimumab/rituximab) 1, 3

Expected Six-Month Outcomes for This Patient

Clinical Improvement:

• Resolution of fatigue, arthritis, and malar rash
• Normalization of fever
• Improved complement levels (C3, C4)
• Decreased anti-dsDNA antibodies

Renal Response:

• Target: Proteinuria reduced by ≥50% from baseline, ideally approaching <0.5 g/g
• Stable or improved eGFR
• Median time to proteinuria <0.5 g/g: Approximately 3.6 months with optimal therapy 1

Laboratory Monitoring (Every 4-6 Weeks During Induction):

• Complete blood count (monitor for leukopenia, anemia)
• Comprehensive metabolic panel (kidney function, electrolytes)
• Urinalysis with protein-creatinine ratio
• Complement levels (C3, C4)
• Anti-dsDNA antibodies
• Hydroxychloroquine blood level (target >0.6 mg/L to reduce flare risk) 1

Maintenance Therapy (After 6-Month Induction)

If Complete or Partial Response Achieved:

• Continue MMF: Reduced dose (1-2 g/day) for at least 24-36 months 1
• Prednisone: Taper to ≤5-7.5 mg/day or discontinue if possible
• Hydroxychloroquine: Continue indefinitely (reduces flare rates and organ damage) 1, 2
• RAS blockade: Continue long-term

Alternative Maintenance Options (if MMF not tolerated):

• Azathioprine 2 mg/kg/day
• Calcineurin inhibitors (tacrolimus, cyclosporine)
• Leflunomide (contraindicated if pregnancy planned within 2 years) 1

Critical Pitfalls to Avoid

1. Inadequate hydroxychloroquine dosing: Doses <5 mg/kg/day may not achieve therapeutic blood levels and increase flare risk 1
2. Premature steroid discontinuation: Maintain low-dose prednisone (≤7.5 mg/day) during maintenance to prevent flares
3. Insufficient proteinuria monitoring: Response is continuous over time; assess every 4-6 weeks initially, then every 3 months 1
4. Delayed response recognition: Some patients require >12 months to achieve complete response; don't switch therapy prematurely if showing gradual improvement 1
5. Neglecting cardiovascular risk: African-American women with SLE have significantly elevated CV mortality; aggressive risk factor management is essential 1
6. Ignoring fertility preservation: Discuss before starting any immunosuppression, particularly if cyclophosphamide considered 1

Long-Term Prognosis

With appropriate treatment, this patient has excellent prognosis:

• Class III lupus nephritis responds well to immunosuppression (60-80% achieve complete or partial response) 1, 3
• Early treatment prevents progression to kidney failure
• Hydroxychloroquine reduces long-term organ damage and mortality 1, 2
• Key to success: Medication adherence, regular monitoring, and prompt treatment of flares

Risk factors requiring closer monitoring in this patient:

• African-American ethnicity (higher risk of severe disease and kidney progression)
• Young age at diagnosis (longer disease duration, cumulative damage risk)
• Class III nephritis with high activity (elevated anti-dsDNA, low complements)